Dibekacin, a new parenteral aminoglycoside, was compared with gentamicin in vitro against 221 clinical isolates. Tests for minimum inhibitory concentrations, performed in agar, demonstrated that dibekacin was comparable to gentamicin against most isolates tested. Dibekacin was slightly more active than gentamicin against some isolates of Pseudomonas aeruginosa, but was significantly less active against strains of Serratia.
Dibekacin (DBK) is a semisynthetic parenteral aminoglycoside antibiotic derived from kanamycin B which differs from it primarily by the absence of the 3' and 4' hydroxyl groups (10) . Results of enzymological studies have demonstrated that these modifications convey to DBK resistance to phosphorylation or adenylation at these sites and resistance to acetylation of the 3-amino group of the 2-deoxystreptamine ring (2, 5) . Pharmacokinetic studies suggest that, despite the structural similarity to kanamycin, serum levels obtained with dosages of 80 to 100 mg given every 8 to 12 h more closely approximate those of gentamicin (GM) (8) . Duval (4), and E. cloacae (8) .
Laboratory reference strains of E. coli (ATCC 25922), P. aeruginosa (ATCC 27853), and S. aureus (ATCC 25923) were employed as controls in all experiments. The MICs of DBK and GM in agar for the reference strain of E. coli were 1.0 and 0.5 ,ug/ml, respectively, 1.0 ,ug/ml each for the strain of P. aeruginosa, and <O.125 ,ug/ml each for S. aureus. Laboratory standard antibiotic powders of DBK and GM were provided by USV Laboratories, Division of Developmental Therapeutics, Tuckahoe, N.Y. MICs were determined by using Mueller-Hinton agar (Difco Laboratories, Detroit, Mich.) by previously described methods (3). Agar dilution tests were used employing a Steers replicating device (9) with an inoculum of approximately 5 8 -fold higher and the MIC9o was 32-fold higher than those for GM. No statistically significant differences were seen when the drugs were compared against those isolates with an MIC of c2 ,ug antibiotic per ml, except for isolates of Serratia marcescens, where the cumulative percentage inhibited by GM at that concentration of antibiotic was significantly higher (94 versus 19%; P < 0.05, Fischer's exact test). With 25 isolates of P. aeruginosa susceptible to GM, both DBK and GM were comparable in antibacterial activity, with all isolates being inhibited by c4.0 ,ug of DBK per ml. Table 2 summarizes the results of a similar comparison of the responses to GM and DBK of 26 GM-resistant isolates (MIC > 8 ,ug/ml). The MICs of DBK were lower than those of GM for six isolates of P. aeruginosa, seven of nine isolates of S. marcescens, and one of five isolates of S. aureus. With two isolates of S. marcescens, the MIC of GM was less than that of DBK.
Paradelis (7) tested 200 isolates of P. aerugi- In conclusion, the antibacterial activity of DBK was comparable to that of GM against GM-susceptible isolates of most gram-negative bacilli tested, including P. aeruginosa. However, the drug was less active against isolates of GMsusceptible S. marcescens. With GM-resistant isolates of P. aeruginosa and other bacteria, DBK was found to have an activity equivalent to that of GM, except for a few isolates in which DBK was slightly more active than GM. These results found with agar dilution testing are different from previously reported studies with broth dilution in which DBK was found to be on September 19, 2017 by guest http://aac.asm.org/ Downloaded from considerably more active against GM-resistant isolates of P. aeruginosa (7) . Differences in methodology and aminoglycoside-modifying enzymes present in respective strains may account for some of the discrepancies reported. Further studies are needed to more clearly define the potential role for DBK in the treatment of infections caused by GM-resistant bacteria.
